The substantial advances attained by checkpoint blockade immunotherapies have driven an expansion in the approaches used to promote T cell access to the tumor microenvironment to provide targets for checkpoint immunotherapy. Inherent in any T cell response to a tumor antigen is the capacity of dendritic cells to initiate and support such responses. Here, the rationale and early immunobiology of CD40 as a master regulator of dendritic cell activation is reviewed, with further contextualization and appreciation for the role of CD40 stimulation not only in cancer vaccines but also in other contemporary immune-oncology approaches.
CITATION STYLE
Bullock, T. N. J. (2022, January 1). CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cellular and Molecular Immunology. Springer Nature. https://doi.org/10.1038/s41423-021-00734-4
Mendeley helps you to discover research relevant for your work.